Micro-PET imaging and small animal models of disease

Current Opinion in Immunology

Volumn 15, Issue 4, 2003, Pages 378-384

  Herschman, Harvey R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; ANTIBODY; CYCLOOXYGENASE 2; ENZYME ANTIBODY; FLUORODEOXYGLUCOSE F 18; GLUCOSE 6 PHOSPHATE ISOMERASE; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; TRACER;

AUTOIMMUNITY; CANCER LOCALIZATION; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; IMAGING SYSTEM; IMMUNOLOGY; ISOTOPE LABELING; LYMPHOMA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REPORTER GENE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0042242608     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(03)00066-9     Document Type: Review

References (51)

1. Phelps M.E. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA. 97:2000;9226-9233.
2. Gambhir S.S., Herschman H.R., Cherry S.R., Barrio J.R., Satyamurthy S., Toyokuni T., Phelps M.E., Balatoni J., Finn R., Tjuvajev J., Blasberg R. Imaging transgene expression with radionuclide imaging technologies. Neoplasia. 2:2000;118-138.
3. Chatziioannou A.F., Cherry S.R., Shao Y., Silverman R.W., Meadors K., Farquhar T.H., Pedarsani M., Phelps M.E. Performance evaluation of microPET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging. J Nucl Med. 40:1999;1164-1175.
4. Tai Y.C., Chatziioannou A., Siegel S., Young J., Newport D., Goble R.N., Nutt R.E., Cherry S.R. Performance evaluation of the microPET P4: a PET system dedicated to animal imaging. Phys Med Biol. 46:2001;1845-1862.
5. Chatziioannou A., Tai Y.C., Doshi N., Cherry S.R. Detector development for microPET II: a 1 microl resolution PET scanner for small animal imaging. Phys Med Biol. 46:2001;2899-2910.
6. Shields A.F., Grierson J.R., Dohmen B.M., Machulla H.J., Stayanoff J.C., Lawhorn-Crews J.M., Obradovich J.E., Muzik O., Mangner T.J. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 4:1998;1334-1336.
7. Gambhir S.S. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2:2002;683-693.
8. Tjuvajev J.G., Avril N., Oku T., Sasajima T., Miyagawa T., Joshi R., Safer M., Beattie B., DiResta G., Daghighian F.et al. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. 58:1998;4333-4341.
9. Tjuvajev J.G., Joshi A., Callegari J., Lindsley L., Joshi R., Balatoni J., Finn R., Larson S.M., Sadelain M., Blasberg R.G. A general approach to the non-invasive imaging of transgenes using cis-linked herpes simplex virus thymidine kinase. Neoplasia. 1:1999;315-320.
10. Gambhir S.S., Barrio J.R., Phelps M.E., Iyer M., Namavari M., Satyamurthy N., Wu L., Green L.A., Bauer E., MacLaren D.C.et al. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci USA. 96:1999;2333-2338.
11. Alauddin M.M., Shahinian A., Kundu R.K., Gordon E.M., Conti P.S. Evaluation of 9-[(3-18F-fluoro-1-hydroxy-2-propoxy)methyl] guanine ([18F]-FHPG) in vitro and in vivo as a probe for PET imaging of gene incorporation and expression in tumors. Nucl Med Biol. 26:1999;371-376.
12. Alauddin M.M., Conti P.S., Mazza S.M., Hamzeh F.M., Lever J.R. Synthesis of 9-[(3-[18F]fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]FHPG): A potential imaging agent of viral infection and gene therapy using PET. Nucl Med Biol. 23:1996;787-792.
13. Alauddin M.M., Conti P.S. Synthesis and preliminary evaluation of 9-(4-[18F]-fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. Nucl Med Biol. 25:1998;175-180.
14. 18F]-Fluoropenciclovir: an improved reporter probe for imaging HSV1-tk reporter gene expression in vivo using positron emission tomography. J Nucl Med. 42:2001;96-105.
15. Tjuvajev J.G., Doubrovin M., Akhurst T., Cai S., Balatoni J., Alauddin M.M., Finn R., Bornmann W., Thaler H., Conti P.S., Blasberg R.G. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med. 43:2002;1072-1083.
16. Brust P., Haubner R., Friedrich A., Scheunemann M., Anton M., Koufaki O.N., Hauses M., Noll S., Noll B., Haberkorn U.et al. Comparison of [18F]FHPG and [124/125I]FIAU for imaging herpes simplex virus type 1 thymidine kinase gene expression. Eur J Nucl Med. 28:2001;721-729.
17. Black M.E., Newcomb T.G., Wilson H.-M.P., Loeb L.A. Creation of drug-specific Herpes Simplex Virus type 1 thymidine kinase mutant for gene therapy. Proc Natl Acad Sci USA. 93:1996;3525-3529.
18. Gambhir S.S., Bauer E., Black M.E., Liang Q., Kokoris M.S., Barrio J.R., Iyer M., Namavari M., Satyamurthy N., Green L.A.et al. A mutant herpes simplex virus Type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci USA. 97:2000;2785-2790.
19. Luker G.D., Sharma V., Pica C.M., Dahlheimer J.L., Li W., Ochesky J., Ryan C.E., Piwnica-Worms H., Piwnica-Worms D. Noninvasive imaging of protein-protein interactions in living animals. Proc Natl Acad Sci USA. 99:2002;6961-6966 This is the first published application of PET imaging to non-invasive monitoring of the interaction of two proteins in a living mouse. The experiment monitors protein-protein interaction-dependent activation of a promoter driving the HSV1-TK PRG as a result of the interaction of a DNA-binding domain and an activation domain.
20. Barrio J.R., Satyamurthy N., Huang S.C., Keen R.E., Nissenson C.H., Hoffman J.M., Ackermann R.F., Bahn M.M., Mazziotta J.C., Phelps M.E. 3-(2'-[18F]fluoroethyl)spiperone: in vivo biochemical and kinetic characterization in rodents, nonhuman primates, and humans. J Cereb Blood Flow Metab. 9:1989;830-839.
21. Satyamurthy N., Barrio J.R., Bida G.T., Huang S.C., Mazziotta J.C., Phelps M.E. 3-(2'-[18F]fluoroethyl)spiperone, a potent dopamine antagonist: synthesis, structural analysis and in-vivo utilization in humans. Int J Rad Appl Instrum. 41:1990;113-129.
22. Ehrin E., Farde L., de Paulis T., Eriksson L., Greitz T., Johnstrom P., Litton J.E., Nilsson J.L., Sedvall G., Stone-Elander S.et al. Preparation of 11C-labelled Raclopride, a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in the monkey. Int J Appl Radiat Isot. 36:1985;269-273.
23. 2 receptor as a reporter gene in living animals. Gene Ther. 6:1999;785-791.
24. Neve K.A., Cox B.A., Henningsen R.A., Spanoyannis A., Neve R.L. Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase. Mol Pharmacol. 39:1991;733-739.
25. 2 receptors. J Neurochem. 59:1992;627-635.
26. Liang Q., Satyamurthy N., Barrio J.R., Toyokuni T., Phelps M.P., Gambhir S.S., Herschman H.R. Noninvasive, quantitative imaging, in living animals, of a mutant dopamine D2 receptor reporter gene in which ligand binding is uncoupled from signal transduction. Gene Ther. 8:2001;1490-1498.
27. 90Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector. Cancer. 94:2002;1298-1305.
28. Zinn K.R., Chaudhuri T.R., Krasnykh V.N., Buchsbaum D.J., Belousova N., Grizzle W.E., Curiel D.T., Rogers B.E. Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice. Radiology. 223:2002;417-425.
29. Zinn K.R., Chaudhuri T.R. The type 2 human somatostatin receptor as a platform for reporter gene imaging. Eur J Nucl Med Mol Imaging. 29:2002;388-399.
30. Chung J.-K. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 43:2002;1188-1200.
31. Spitzweg C., Morris J.C. Approaches to gene therapy with sodium/iodide symporter. Exp Clin Endocrinol Diabetes. 109:2001;56-59.
32. Herschman HR, Barrio JR, Satyamurthy N, Liang Q, MacLaren DC, Yaghoubi S, Toyokuni T, Cherry SR, Phelps ME, Gambhir SS: Monitoring gene therapy by positron emission tomography. In Vector Targeting for Therapeutic Gene Delivery. Edited by Curiel DT, Douglas JT. New York: Wiley-Liss; 2002:661-685.
33. Yu Y., Annala A.J., Barrio J.R., Toyokuni T., Satyamurthy N., Namavari M., Cherry S.R., Phelps M.E., Herschman H.R., Gambhir S.S. Quantification of target gene expression by imaging reporter gene expression in living animals. Nat Med. 6:2000;933-937.
34. •], each animal was imaged twelve times by micro-PET over a three month observation period. These experiments demonstrate that repeated imaging of a PET reporter gene in a bicistronic message permits the indirect, quantitative evaluation of relative gene expression of a gene of interest by the non-invasive measurement of a PET reporter gene.
35. Sun X., Annala A.J., Yaghoubi S., Barrio J.R., Nguyen K., Toyokuni T., Satyamurthy N., Namavari M., Phelps M.E., Herschman H.R., Gambhir S.S. Quantitative imaging of gene induction in living animals. Gene Ther. 8:2001;1572-1579.
36. Yaghoubi S.S., Wu L., Liang Q., Toyokuni T., Barrio J.R., Namavari M., Satyamurthy N., Phelps M.E., Herschman H.R., Gambhir S.S. Direct correlation between positron emission tomographic images of two reporter genes delivered by two distinct adenoviral vectors. Gene Ther. 8:2001;1072-1080.
37. Wipke B.T., Wang Z., Kim J., McCarthy T.J., Allen P.M. Dynamic visualization of a joint-specific autoimmune response through positron emission tomography. Nat Immunol. 3:2002;366-372 The non-invasive characteristics of PET imaging were used to demonstrate the rapid and increasing binding of anti-GPI antibody to normal joints, suggesting 'first pass' removal of antibody to pre-formed antigen targets in this model of an autoimmune disease.
38. 4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci USA. 99:2002;3030-3035.
39. ••].
40. ••] are the first examples of the use of non-invasive PET reporter gene imaging to analyze the time-dependent accumulation of antigen-specific T cells at the site of a tumor. The use of distinct cell systems emphasizes the potential and power of the ability of non-invasive imaging of T-cell trafficking to contribute to the understanding of immunological events. This technology could be transferred to clinical contexts in a straightforward manner.
41. Ponomarev V., Doubrovin M., Lyddane C., Beresten T., Balatoni J., Bornman W., Finn R., Akhurst T., Larson S., Blasberg R.et al. Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. Neoplasia. 3:2001;480-488.
42. Kabarowski J.H., Zhu K., Le L.Q., Witte O.N., Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science. 293:2001;702-705.
43. Le L.Q., Kabarowski J.H.S., Wong S., Nguyen K., Gambhir S.S., Witte O.N. Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene. Cancer Cells. 1:2002;381-391 The ability to non-invasively monitor tumor-cell expansion before clinical symptoms appear provides the opportunity to monitor alternative therapeutic regimens in a longitudinal fashion, starting with very early levels of tumor burden.
44. 124I-CDR-grafted humanized A33 monoclonal antibody. J Nucl Med. 42:2001;764-769.
45. Wu A.M., Yazaki P.J., Tsai S., Nguyen K., Anderson A.-L., McCarthy D.W., Welch M.J., Shively J.E., Williams L.E., Raubitschek A.A.et al. High-resolution microPET imaging of carcino-embryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci USA. 97:2000;8495-8500.
46. Herschman HR: Historical aspects of COX-2; cloning and characterization of the cDNA, protein and gene. In COX-2 Blockage in Cancer Prevention and Therapy. Edited by Harris R. Humana Press; 2003:13-32.
47. 18F-labeled COX-1 and COX-2 inhibitors. J Nucl Med. 43:2002;117-124.
48. Ortu G., Ben-David I., Rozen Y., Freedman N.M.T., Chisin R., Levitzki A., Mishani E. Labeled EGFR-TK irreversible inhibitor (ML03): In vitro and in vivo properties, potential as pet biomarker for cancer and feasibility as anticancer drug. Int J Cancer. 101:2002;360-370.
49. Contag C.H., Bachmann M.H. Advances in In vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng. 4:2002;235-260.
50. O'Connell-Rodwell CE, Burns SM, Bachmann MH, Contag CH: Bioluminescent indicators for in vivo measurements of gene expression. Trends Biotech 20:S19-S23.
51. Ray P., Wu A.M., Gambhir S.S. Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice. Cancer Res. 63:2003;1160-1165.